Matthew Gantz, Castle Creek CEO

A Jeff Aronin start­up qui­et­ly yanks its IPO as the biotech mar­ket ends year on a whim­per

Close to 6 months af­ter it ini­tial­ly post­ed its S-1 in what was still a thriv­ing biotech IPO mar­ket, Cas­tle Creek Bio­sciences has now yanked the of­fer­ing as new deals fade against the back­ground of a hard, year-end ap­praisal for drug stocks.

In its fil­ing with the SEC, Cas­tle Creek CEO Matthew Gantz mere­ly states that the biotech is no longer pur­su­ing an IPO. He had ini­tial­ly pen­ciled in a $100 mil­lion raise last sum­mer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.